Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer

por van der Noll, R., Smit, W. M., Wymenga, A. N. M., Boss, D. S., Grob, M., Huitema, A. D. R., Rosing, H., Tibben, M. M., Keessen, M., Rehorst, H., Beijnen, J. H., Schellens, J. H. M.
Publicado 2015

Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy

por Hannemann, J, Kristel, P, van Tinteren, H, Bontenbal, M, van Hoesel, Q G C M, Smit, W M, Nooij, M A, Voest, E E, van der Wall, E, Hupperets, P, de Vries, E G E, Rodenhuis, S, van de Vijver, M J
Publicado 2006

High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study

por Deenik, W., van der Holt, B., Verhoef, G. E. G., Schattenberg, A. V. M. B., Verdonck, L. F., Daenen, S. M. G. J., Zachée, P., Westveer, P. H. M., Smit, W. M., Wittebol, S., Schouten, H. C., Löwenberg, B., Ossenkoppele, G. J., Cornelissen, J. J.
Publicado 2006